1. Home
  2. SLN vs ALT Comparison

SLN vs ALT Comparison

Compare SLN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • ALT
  • Stock Information
  • Founded
  • SLN 1994
  • ALT 1997
  • Country
  • SLN United Kingdom
  • ALT United States
  • Employees
  • SLN N/A
  • ALT N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLN Health Care
  • ALT Health Care
  • Exchange
  • SLN Nasdaq
  • ALT Nasdaq
  • Market Cap
  • SLN 299.4M
  • ALT 292.0M
  • IPO Year
  • SLN N/A
  • ALT N/A
  • Fundamental
  • Price
  • SLN $4.81
  • ALT $3.83
  • Analyst Decision
  • SLN Buy
  • ALT Strong Buy
  • Analyst Count
  • SLN 5
  • ALT 6
  • Target Price
  • SLN $32.60
  • ALT $17.40
  • AVG Volume (30 Days)
  • SLN 60.5K
  • ALT 3.0M
  • Earning Date
  • SLN 08-07-2025
  • ALT 08-12-2025
  • Dividend Yield
  • SLN N/A
  • ALT N/A
  • EPS Growth
  • SLN N/A
  • ALT N/A
  • EPS
  • SLN N/A
  • ALT N/A
  • Revenue
  • SLN $27,169,000.00
  • ALT $20,000.00
  • Revenue This Year
  • SLN N/A
  • ALT N/A
  • Revenue Next Year
  • SLN N/A
  • ALT $761,880.20
  • P/E Ratio
  • SLN N/A
  • ALT N/A
  • Revenue Growth
  • SLN 22.28
  • ALT N/A
  • 52 Week Low
  • SLN $1.97
  • ALT $2.90
  • 52 Week High
  • SLN $20.48
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • SLN 34.88
  • ALT 51.79
  • Support Level
  • SLN $4.91
  • ALT $3.35
  • Resistance Level
  • SLN $5.34
  • ALT $3.66
  • Average True Range (ATR)
  • SLN 0.48
  • ALT 0.19
  • MACD
  • SLN -0.05
  • ALT 0.07
  • Stochastic Oscillator
  • SLN 0.71
  • ALT 86.18

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: